Clinical Trial: Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL)
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
Detailed Summary:
Sponsor: University of Kansas Medical Center
Current Primary Outcome:
- Response Rate [ Time Frame: 24 months ]
- type, incidence, severity, seriousness and relationship to auranofin of adverse events and any laboratory abnormalities [ Time Frame: 24 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University of Kansas Medical Center
Dates:
Date Received: August 16, 2011
Date Started: September 2011
Date Completion:
Last Updated: January 15, 2016
Last Verified: January 2016
